Cargando…
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer
Activating mutations in KRAS (KRAS*) are present in nearly all pancreatic ductal adenocarcinoma (PDAC) cases and critical for tumor maintenance. By using an inducible KRAS* PDAC mouse model, we identified a deubiquitinase USP21-driven resistance mechanism to anti-KRAS* therapy. USP21 promotes KRAS*-...
Autores principales: | Hou, Pingping, Ma, Xingdi, Yang, Zecheng, Zhang, Qiang, Wu, Chang-Jiun, Li, Jun, Tan, Lin, Yao, Wantong, Yan, Liang, Zhou, Xin, Kimmelman, Alec C., Lorenzi, Philip L., Zhang, Jianhua, Jiang, Shan, Spring, Denise, Wang, Y. Alan, DePinho, Ronald A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494209/ https://www.ncbi.nlm.nih.gov/pubmed/34531315 http://dx.doi.org/10.1101/gad.348787.121 |
Ejemplares similares
-
USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation
por: Hou, Pingping, et al.
Publicado: (2019) -
Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu, Xinquan, et al.
Publicado: (2019) -
Anticipating resistance to KRAS inhibition: a novel role for USP21 in macropinocytosis regulation
por: Crawford, Howard C.
Publicado: (2021) -
Conquering oncogenic KRAS and its bypass mechanisms
por: Hou, Pingping, et al.
Publicado: (2022) -
Up‐regulated deubiquitinase USP4 plays an oncogenic role in melanoma
por: Guo, Weinan, et al.
Publicado: (2018)